Orphazyme finds reduced Niemann-Pick disease progression in trial

beaker_glass_wear_chemical_lab_glass_science_experiment_chemistry-1367344 2
Orphazyme has reported positive interim results from an open-label extension study of a Phase II/III clinical trial of arimoclomol in patients with NPC. Credit: Pxhere.